J&J Medical Connect
icotrokinra
+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

icotrokinra

Medical Information

Icotrokinra – Treatment of Atopic Dermatitis

Last Updated: 09/03/2025

SUMMARY  

  • Icotrokinra (JNJ-77242113) is a targeted oral peptide that selectively binds the interleukin-23 (IL-23) receptor and inhibits IL-23 pathway signaling and is an investigational agent that is being studied for the treatment of moderate to severe plaque psoriasis (PsO) in adult and pediatric patients.1   
  • There is no relevant data available regarding the use of icotrokinra for the treatment of atopic dermatitis.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 06 August 2025 did not identify any relevant citations pertaining to this topic.

REFERENCES